Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of “Buy” from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have been given a consensus rating of “Buy” by the nine analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and three have assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $6.60.

Several equities analysts have recently weighed in on IMUX shares. D. Boral Capital decreased their price target on shares of Immunic from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. Chardan Capital raised shares of Immunic to a “strong-buy” rating in a research report on Wednesday, November 19th. Roth Mkm assumed coverage on shares of Immunic in a research report on Friday, November 7th. They set a “buy” rating and a $3.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Immunic in a research note on Monday, February 9th.

Immunic Price Performance

Shares of Immunic stock opened at $0.91 on Thursday. The firm has a market cap of $118.77 million, a price-to-earnings ratio of -1.10 and a beta of 1.58. The stock’s 50-day moving average is $0.68 and its 200-day moving average is $0.76. Immunic has a one year low of $0.51 and a one year high of $1.35.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC raised its stake in shares of Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after purchasing an additional 152,726 shares in the last quarter. HB Wealth Management LLC acquired a new position in Immunic during the third quarter worth $81,000. Vanguard Group Inc. raised its position in Immunic by 5.3% during the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after acquiring an additional 219,957 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Immunic in the third quarter valued at $170,000. Finally, Squarepoint Ops LLC bought a new position in shares of Immunic in the 3rd quarter valued at about $239,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.